What is the primary treatment for moderate persistent asthma for children aged 5-11?

The primary treatment for moderate persistent asthma in children aged 5-11 typically involves the use of a medium dose of inhaled corticosteroids (ICS). Inhaled corticosteroids are the cornerstone of asthma management because they effectively reduce inflammation in the airways, which is a key component of asthma pathophysiology.

For children in this age group with moderate persistent asthma, a medium dose of ICS is recommended as it provides a balance between efficacy and safety. It is effective in controlling symptoms and preventing exacerbations while minimizing side effects that can be associated with higher doses of medication. Additionally, children may not always tolerate higher doses, making medium doses a suitable option for maintaining control over asthma symptoms.

While long-acting beta agonists (LABAs) can be included in treatment plans, they should typically be used in conjunction with ICS rather than as standalone treatments. Montelukast, a leukotriene receptor antagonist, can be effective as an alternative treatment or add-on therapy, but it is not the primary therapy for moderate persistent asthma in this age group. Therefore, the medium dose of ICS stands out as the most appropriate primary treatment option for managing moderate persistent asthma in children aged 5-11.